1. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9980 (9th May 2015) Authors: Moskowitz, Craig H; Nademanee, Auayporn; Masszi, Tamas; Agura, Edward; Holowiecki, Jerzy; Abidi, Muneer H; Chen, Andy I; Stiff, Patrick; Gianni, Alessandro M; Carella, Angelo; Osmanov, Dzhelil; Bachanova, Veronika; Sweetenham, John; Sureda, Anna; Huebner, Dirk; Sievers, Eric L; Chi, Andy; Larsen,... Journal: Lancet Issue: Volume 385:Issue 9980(2015) Page Start: 1853 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis. (July 2015) Authors: Bonthapally, Vijayveer; Yang, Hongbo; Ayyagari, Rajeev; Tan, Ruo-Ding; Cai, Sean; Wu, Eric; Gautam, Ashish; Chi, Andy; Huebner, Dirk Journal: Current medical research and opinion Issue: Volume 31:Number 7(2015:Jul.) Page Start: 1377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat. Issue 1 (2nd January 2018) Authors: Gautam, Ashish; Zhu, Yanyan; Ma, Esprit; Lee, Shih-Yuan; Zagadailov, Erin; Teasell, Jeremy; Richhariya, Akshara; Bonthapally, Vijayveer; Huebner, Dirk Journal: Leukemia & lymphoma Issue: Volume 59:Issue 1(2018) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. (May 2015) Authors: Bonthapally, Vijayveer; Wu, Eric; Macalalad, Alexander; Yang, Hongbo; Shonukan, Oluwatoyin; Liu, Yi; Chi, Andy; Huebner, Dirk Journal: Current medical research and opinion Issue: Volume 31:Number 5(2015:May) Page Start: 993 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Issue 10094 (5th August 2017) Authors: Prince, H Miles; Kim, Youn H; Horwitz, Steven M; Dummer, Reinhard; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Sanches, Jose A; Ortiz-Romero, Pablo L; Akilov, Oleg E; Geskin, Larisa; Trotman, Judith; Taylor, Kerry; Dalle, Stephane; Weichenthal, Michael; Walewski, Ja... Journal: Lancet Issue: Volume 390:Issue 10094(2017) Page Start: 555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. Issue 4 (April 2015) Authors: Forero-Torres, Andres; Bartlett, Nancy L.; Berryman, Robert B.; Chen, Robert; Matous, Jeffrey V.; Fanale, Michelle A.; O'Connor, Owen A.; Olshefski, Randal; Smith, Scott E.; Huebner, Dirk; Levine, Pamela L.; Grove, Laurie E.; Gopal, Ajay K. Journal: Leukemia & lymphoma Issue: Volume 56:Issue 4(2015:Apr.) Page Start: 1151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia. (24th November 2017) Authors: Zhou, Xiaofei; Mould, Diane R.; Takubo, Takatoshi; Sheldon‐Waniga, Emily; Huebner, Dirk; Milton, Ashley; Venkatakrishnan, Karthik Journal: British journal of clinical pharmacology Issue: Volume 84:Number 1(2018:Jul.) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. (March 2016) Authors: Zinzani, Pier Luigi; Bonthapally, Vijayveer; Huebner, Dirk; Lutes, Richard; Chi, Andy; Pileri, Stefano Journal: Critical reviews in oncology/hematology Issue: Volume 99(2016) Page Start: 228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. (March 2016) Authors: Zinzani, Pier Luigi; Bonthapally, Vijayveer; Huebner, Dirk; Lutes, Richard; Chi, Andy; Pileri, Stefano Journal: Critical reviews in oncology/hematology Issue: Volume 99(2016) Page Start: 214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. (21st September 2018) Authors: Bröckelmann, Paul J.; McMullen, Suzanne; Wilson, J Ben; Mueller, Kerstin; Goring, Sarah; Stamatoullas, Aspasia; Zagadailov, Erin; Gautam, Ashish; Huebner, Dirk; Dalal, Mehul; Illidge, Tim Journal: British journal of haematology Issue: Volume 184:Number 2(2019) Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗